Sector News

Edwards Announces Board Change

October 6, 2014
Life sciences
/PRNewswire/ – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that David E.I. Pyott, a member of the company’s Board of Directors, has submitted his resignation, effective today, in order to devote more time to his role as chairman and chief executive officer of Allergan, Inc.
 
“The board and I are truly appreciative of David’s service and commitment to Edwards during the last 14 years,” said Michael A. Mussallem, Edwards’ chairman and CEO.  “David’s extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company.  He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients.  We wish him the best and thank him for the significant role he has played in Edwards’ growth and success.”
 
Pyott joined Edwards’ board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.
 
Source: Edwards Lifesciences Corporation

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach